Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer.
Green
Mark R
MR
Network for Medical Communication and Research Analytics, Atlanta, GA, USA.
D006585:Altretamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design
D008130:Lomustine; D003520:Cyclophosphamide; D006585:Altretamine; D008727:Methotrexate